Enterprise Value

2.181B

Cash

228.6M

Avg Qtr Burn

N/A

Short % of Float

13.21%

Insider Ownership

4.94%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Gocovri (Amantadine) Details
Dyskinesia (Parkinson's disease)

Approved

Quarterly sales

Namzaric Details
Alzheimer's Dementia

Approved

Quarterly sales

Osmolex ER (amantadine) Details
PD (Parkinson's Disease)

Approved

Quarterly sales

MYOBLOC® (rimabotulinumtoxinB) Details
Cervical Dystonia Sialorrhea

Approved

Quarterly sales

Qelbree (viloxazine hydrochloride) Details
Attention deficit hyperactivity disorder (ADHD)

Approved

Quarterly sales

Approved

Quarterly sales

Gocovri (Amantadine) Details
Parkinson's disease for OFF episodes

Approved

Quarterly sales

Trokendi XR® (topiramate) Details
Prophylaxis of migraine

Approved

Quarterly sales

XADAGO (safinamide) Details
Parkinson's disease

Approved

Quarterly sales

SPN-830 Details
Parkinson's disease, Brain disease

NDA

Resubmission

SPN-820 Details
Treatment Resistant Depression, Mental health

Phase 2

Data readout

Phase 2

Data readout